Last reviewed · How we verify
LY333531
At a glance
| Generic name | LY333531 |
|---|---|
| Sponsor | Chromaderm, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Randomized and Open Label Study for Safety and Efficacy of DBI-102 vs. Vehicle vs. Hydroquinone on Skin Pigmentation and Lentigos (PHASE2)
- Ruboxistaurin in New York Heart Failure Classification III-IV Patients (PHASE1, PHASE2)
- The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes (PHASE2)
- Treatment for Completers of the Study B7A-MC-MBCM (PHASE3)
- Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study (PHASE3)
- Effect of Ruboxistaurin on Clinically Significant Macular Edema (PHASE3)
- Reduction in the Occurrence of Center-Involved Diabetic Macular Edema (PHASE3)
- Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY333531 CI brief — competitive landscape report
- LY333531 updates RSS · CI watch RSS
- Chromaderm, Inc. portfolio CI